drugset
drugset / Trial / NCT00415454

Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma

NCT00415454 ↗

Phase 1 Terminated 8 enrolled Henry Ford Health System
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary purpose of this phase I study is to determine the safety of combining replication-competent adenovirus-mediated suicide gene therapy with chemoradiotherapy in patients with non-metastatic pancreatic cancer.

Timeline

Start
2006-11
Primary completion
—
Completion
—

Outcome

Outcome not reported

Stopped (Enrollment): “Poor enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad5-yCD/mutTKSR39rep-ADP Unknown 1e+10 vg Intrathecal
Subject Ad5-yCD/mutTKSR39rep-ADP Unknown 3e+10 vg Intrathecal
Subject Ad5-yCD/mutTKSR39rep-ADP Unknown 1e+11 vg Intrathecal
Subject Ad5-yCD/mutTKSR39rep-ADP Unknown 3e+11 vg Intrathecal
Subject Ad5-yCD/mutTKSR39rep-ADP Unknown 1e+12 vg Intrathecal

Indications

malignant pancreatic neoplasm